Concepts (128)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Bronchial Fistula | 2 | 2010 | 24 | 0.620 |
Why?
|
| Pleural Diseases | 2 | 2010 | 31 | 0.620 |
Why?
|
| Liver Failure, Acute | 1 | 2020 | 94 | 0.570 |
Why?
|
| Echocardiography | 3 | 2020 | 1124 | 0.560 |
Why?
|
| Shock, Cardiogenic | 1 | 2020 | 176 | 0.540 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2013 | 2061 | 0.470 |
Why?
|
| Dyspnea | 2 | 2013 | 159 | 0.450 |
Why?
|
| Clinical Competence | 2 | 2019 | 1046 | 0.380 |
Why?
|
| Pulmonary Edema | 1 | 2013 | 54 | 0.370 |
Why?
|
| Endocarditis | 1 | 2013 | 102 | 0.360 |
Why?
|
| Hypotension | 1 | 2013 | 187 | 0.340 |
Why?
|
| Mitral Valve Insufficiency | 1 | 2013 | 178 | 0.330 |
Why?
|
| Critical Care | 3 | 2019 | 686 | 0.330 |
Why?
|
| Pleura | 1 | 2010 | 27 | 0.310 |
Why?
|
| Antimalarials | 1 | 2009 | 40 | 0.300 |
Why?
|
| Malaria, Falciparum | 1 | 2009 | 58 | 0.300 |
Why?
|
| Thoracotomy | 1 | 2010 | 107 | 0.290 |
Why?
|
| Lung Diseases | 2 | 2013 | 396 | 0.290 |
Why?
|
| Bronchoscopy | 1 | 2010 | 178 | 0.290 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 1 | 2009 | 58 | 0.280 |
Why?
|
| Sjogren's Syndrome | 1 | 2009 | 109 | 0.260 |
Why?
|
| Heart Failure | 1 | 2020 | 2325 | 0.240 |
Why?
|
| Ultrasonography | 3 | 2020 | 942 | 0.200 |
Why?
|
| Sexual and Gender Minorities | 1 | 2022 | 67 | 0.170 |
Why?
|
| Cardiac Output | 2 | 2020 | 153 | 0.170 |
Why?
|
| Pulmonary Embolism | 2 | 2013 | 182 | 0.170 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2021 | 103 | 0.160 |
Why?
|
| Jaundice | 1 | 2020 | 27 | 0.150 |
Why?
|
| Diuretics | 1 | 2020 | 159 | 0.150 |
Why?
|
| Respiratory Insufficiency | 1 | 2021 | 245 | 0.140 |
Why?
|
| Cardiotonic Agents | 1 | 2020 | 138 | 0.140 |
Why?
|
| Tracheal Neoplasms | 1 | 2018 | 21 | 0.140 |
Why?
|
| Oncogene Proteins | 1 | 2018 | 136 | 0.130 |
Why?
|
| Echocardiography, Transesophageal | 1 | 2019 | 246 | 0.130 |
Why?
|
| Stroke Volume | 1 | 2020 | 540 | 0.130 |
Why?
|
| Pulmonary Atelectasis | 1 | 2017 | 15 | 0.130 |
Why?
|
| Point-of-Care Systems | 1 | 2020 | 213 | 0.130 |
Why?
|
| Thrombosis | 1 | 2021 | 498 | 0.120 |
Why?
|
| Bronchiolitis Obliterans | 1 | 2017 | 42 | 0.120 |
Why?
|
| Diagnosis, Differential | 3 | 2013 | 1874 | 0.120 |
Why?
|
| Carcinoma | 1 | 2018 | 291 | 0.120 |
Why?
|
| Radiography, Thoracic | 2 | 2013 | 144 | 0.120 |
Why?
|
| Hypertension, Pulmonary | 2 | 2010 | 454 | 0.110 |
Why?
|
| HIV Infections | 2 | 2022 | 2047 | 0.110 |
Why?
|
| Critical Illness | 1 | 2019 | 625 | 0.110 |
Why?
|
| Humans | 16 | 2022 | 130511 | 0.110 |
Why?
|
| Pandemics | 1 | 2021 | 1115 | 0.100 |
Why?
|
| Middle Aged | 6 | 2021 | 28420 | 0.100 |
Why?
|
| Silicosis | 1 | 2013 | 4 | 0.100 |
Why?
|
| Occupational Diseases | 1 | 2013 | 74 | 0.100 |
Why?
|
| Angiography | 1 | 2013 | 179 | 0.090 |
Why?
|
| Atrial Fibrillation | 1 | 2020 | 736 | 0.090 |
Why?
|
| Nuclear Proteins | 1 | 2018 | 1210 | 0.090 |
Why?
|
| Male | 9 | 2022 | 64586 | 0.080 |
Why?
|
| Mitral Valve | 1 | 2013 | 245 | 0.080 |
Why?
|
| Bronchography | 1 | 2010 | 6 | 0.080 |
Why?
|
| Fibrin Tissue Adhesive | 1 | 2010 | 9 | 0.080 |
Why?
|
| Tomography, Spiral Computed | 1 | 2010 | 14 | 0.080 |
Why?
|
| Iohexol | 1 | 2010 | 19 | 0.080 |
Why?
|
| Heart Valve Prosthesis | 1 | 2013 | 303 | 0.080 |
Why?
|
| Radiographic Image Enhancement | 1 | 2010 | 38 | 0.080 |
Why?
|
| Fistula | 1 | 2010 | 49 | 0.080 |
Why?
|
| Hemostatics | 1 | 2010 | 58 | 0.080 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2009 | 60 | 0.070 |
Why?
|
| Treatment Outcome | 3 | 2021 | 12851 | 0.070 |
Why?
|
| Internship and Residency | 1 | 2019 | 1221 | 0.070 |
Why?
|
| Suture Techniques | 1 | 2010 | 178 | 0.070 |
Why?
|
| Lung Neoplasms | 1 | 2018 | 1545 | 0.070 |
Why?
|
| Rituximab | 1 | 2009 | 170 | 0.070 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2009 | 214 | 0.070 |
Why?
|
| Antirheumatic Agents | 1 | 2009 | 123 | 0.060 |
Why?
|
| Lung Diseases, Interstitial | 1 | 2009 | 166 | 0.060 |
Why?
|
| Follow-Up Studies | 2 | 2021 | 5185 | 0.060 |
Why?
|
| Hemodynamics | 1 | 2010 | 810 | 0.060 |
Why?
|
| Contrast Media | 1 | 2010 | 476 | 0.060 |
Why?
|
| Aged | 5 | 2021 | 20897 | 0.060 |
Why?
|
| Severity of Illness Index | 2 | 2010 | 3038 | 0.050 |
Why?
|
| Antibodies, Monoclonal | 1 | 2009 | 978 | 0.050 |
Why?
|
| Prognosis | 2 | 2009 | 4866 | 0.050 |
Why?
|
| Homosexuality, Male | 1 | 2022 | 58 | 0.050 |
Why?
|
| Adolescent | 3 | 2022 | 20876 | 0.050 |
Why?
|
| Acute Kidney Injury | 1 | 2009 | 702 | 0.050 |
Why?
|
| Partial Thromboplastin Time | 1 | 2021 | 55 | 0.040 |
Why?
|
| Minority Groups | 1 | 2022 | 259 | 0.040 |
Why?
|
| Population Surveillance | 1 | 2022 | 394 | 0.040 |
Why?
|
| Fibrinolytic Agents | 1 | 2021 | 182 | 0.040 |
Why?
|
| Adult | 5 | 2022 | 31115 | 0.040 |
Why?
|
| Female | 6 | 2022 | 70545 | 0.040 |
Why?
|
| Aged, 80 and over | 3 | 2013 | 6772 | 0.030 |
Why?
|
| Predictive Value of Tests | 2 | 2013 | 2298 | 0.030 |
Why?
|
| Computer Simulation | 1 | 2019 | 671 | 0.030 |
Why?
|
| Fatal Outcome | 1 | 2017 | 349 | 0.030 |
Why?
|
| Young Adult | 2 | 2021 | 10033 | 0.030 |
Why?
|
| Neoplasm Proteins | 1 | 2018 | 679 | 0.030 |
Why?
|
| Dentists | 1 | 2013 | 6 | 0.030 |
Why?
|
| Retrospective Studies | 3 | 2021 | 17650 | 0.020 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 2013 | 38 | 0.020 |
Why?
|
| Unnecessary Procedures | 1 | 2013 | 61 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2021 | 3815 | 0.020 |
Why?
|
| Academic Medical Centers | 1 | 2013 | 321 | 0.020 |
Why?
|
| Technetium Tc 99m Pentetate | 1 | 2010 | 6 | 0.020 |
Why?
|
| Radionuclide Imaging | 1 | 2010 | 113 | 0.020 |
Why?
|
| Acute Disease | 1 | 2013 | 1152 | 0.020 |
Why?
|
| Biomarkers, Tumor | 1 | 2018 | 1581 | 0.020 |
Why?
|
| Radiopharmaceuticals | 1 | 2010 | 155 | 0.020 |
Why?
|
| Respiratory Function Tests | 1 | 2010 | 222 | 0.020 |
Why?
|
| Vascular Resistance | 1 | 2010 | 182 | 0.020 |
Why?
|
| Prostaglandins | 1 | 2009 | 35 | 0.020 |
Why?
|
| Endothelin Receptor Antagonists | 1 | 2009 | 13 | 0.020 |
Why?
|
| Dobutamine | 1 | 2009 | 48 | 0.020 |
Why?
|
| Milrinone | 1 | 2009 | 30 | 0.020 |
Why?
|
| Causality | 1 | 2009 | 89 | 0.020 |
Why?
|
| Phosphodiesterase Inhibitors | 1 | 2009 | 54 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2013 | 1243 | 0.020 |
Why?
|
| ROC Curve | 1 | 2010 | 613 | 0.020 |
Why?
|
| Vasoconstrictor Agents | 1 | 2009 | 136 | 0.020 |
Why?
|
| Anti-Retroviral Agents | 1 | 2009 | 154 | 0.020 |
Why?
|
| United States | 1 | 2022 | 12009 | 0.020 |
Why?
|
| Respiration, Artificial | 1 | 2009 | 498 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 2009 | 1165 | 0.010 |
Why?
|
| Blood Pressure | 1 | 2010 | 1344 | 0.010 |
Why?
|
| Lung Transplantation | 1 | 2009 | 359 | 0.010 |
Why?
|
| Comorbidity | 1 | 2009 | 1589 | 0.010 |
Why?
|
| Survival Rate | 1 | 2009 | 2109 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2010 | 2897 | 0.010 |
Why?
|
| Prevalence | 1 | 2009 | 2693 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2010 | 5048 | 0.010 |
Why?
|
| Risk Factors | 1 | 2013 | 11011 | 0.010 |
Why?
|